Kornitzer Capital Management Inc. KS Boosts Holdings in Amgen Inc. $AMGN

Kornitzer Capital Management Inc. KS boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 19.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 18,458 shares of the medical research company’s stock after acquiring an additional 3,024 shares during the period. Kornitzer Capital Management Inc. KS’s holdings in Amgen were worth $6,041,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Board of the Pension Protection Fund acquired a new position in Amgen during the 4th quarter valued at approximately $26,000. Olistico Wealth LLC acquired a new position in Amgen during the 4th quarter valued at approximately $33,000. Cloud Capital Management LLC acquired a new position in Amgen during the 3rd quarter valued at approximately $34,000. Ares Financial Consulting LLC acquired a new position in Amgen during the 4th quarter valued at approximately $34,000. Finally, Saranac Partners Ltd acquired a new position in Amgen during the 3rd quarter valued at approximately $37,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on AMGN shares. The Goldman Sachs Group upped their price target on shares of Amgen from $415.00 to $425.00 and gave the company a “buy” rating in a research note on Friday. Piper Sandler upped their price target on shares of Amgen from $381.00 to $432.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. Wells Fargo & Company upped their price target on shares of Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a research note on Thursday, March 19th. Wall Street Zen lowered shares of Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, Oppenheimer set a $400.00 price target on shares of Amgen and gave the company an “outperform” rating in a research note on Thursday, January 29th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Amgen currently has an average rating of “Hold” and a consensus target price of $357.54.

Amgen Stock Down 4.7%

NASDAQ:AMGN opened at $329.82 on Friday. The firm has a market capitalization of $178.00 billion, a P/E ratio of 22.95, a PEG ratio of 3.26 and a beta of 0.44. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29. The company’s fifty day moving average price is $358.07 and its 200-day moving average price is $340.79. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The firm had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 139.90%. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities research analysts anticipate that Amgen Inc. will post 22.28 EPS for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.1%. Amgen’s dividend payout ratio is presently 70.84%.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q1 results beat expectations — AMGN reported $5.15 EPS vs. $4.73 consensus and product sales rose ~4%, with 16 drugs delivering double‑digit growth, supporting the company’s growth story. Amgen’s Q1 Earnings Top Estimates
• Positive Sentiment: Bullish analyst action — Goldman Sachs reiterated a Buy and lifted its price target to $425, signaling long‑term upside from execution and pipeline momentum. Goldman Sachs Raises PT to $425
• Positive Sentiment: Other supportive analyst notes — Some firms (e.g., William Blair) reiterated Buy ratings after the quarter, highlighting confidence in the MariTide/weight‑loss program and execution. Analyst Reiterates Buy
• Neutral Sentiment: Guidance set but roughly in line — Amgen updated FY‑2026 EPS guidance to $21.70–$23.10 (consensus ~22.29), which many read as broadly in‑line rather than materially bullish. Amgen FY2026 Guidance (press release/slide)
• Neutral Sentiment: Small, mixed analyst target moves — Truist nudged its target to $327 with a Hold rating (minimal change), leaving some investors watching for clearer directional signals. Truist Raises PT to $327
• Negative Sentiment: FDA action risk — The FDA proposed withdrawing Tavneos approval after alleging clinical‑trial data issues, raising regulatory, compliance and reputational concerns that can pressure the stock. FDA Tavneos Proposal Coverage
• Negative Sentiment: Investor apprehension over strategy/timing — Some market commentary framed the quarter as “generally in‑line” and expressed concern about Amgen’s aggressive push into obesity (MariTide) and the near‑term profit impact, contributing to selling pressure. Investor Reaction to MariTide Expansion

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.